Molecular Diagnostics in Cancer Testing

Description: Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays.

These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation.

The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide.

Contents:
1. Overview
   1.1 Statement of Report
   1.2 About This Report
   1.3 Scope of the Report
   1.4 Objectives
   1.5 Methodology
   1.6 Executive Summary

2. Introduction to Molecular Diagnostics
   2.1 Opening of Opportunities in Molecular Diagnostics
   2.2 Impact of the Human Genome Project on Molecular Diagnostics
   2.3 Considerations for Molecular and Clinical Diagnostics
   2.4 Molecular Diagnostics in the Post-Genomic Era
   2.5 Advances in Molecular Diagnostics Technologies
   2.6 Oligonucleotide Array Platforms
   2.7 Emerging Cancer Personalized Medicine Market
     2.7.1 Predictive Cancer Molecular Diagnostics
     2.8 Companion Tests for Drug Development
     2.9 Opportunities for IVD/IMA Companies
     2.10 Next Generation Sequencing (NGS)
     2.11 Multi-Gene Cancer Panels
     2.12 Liquid Biopsy

3. Cancer Diagnostics Molecular Testing Market
   3.1 Market Description
     3.1.1 Market Overview
     3.1.2 Molecular Diagnostic Markers
     3.1.3 Competitive Landscape
     3.1.4 Sales and Marketing Strategies for Cancer Tests
     3.1.4.1 North American Market
     3.1.4.2 International Markets
     3.1.4.3 Europe
     3.1.4.4 Asia-Pacific

4. Molecular Diagnostic Tests for Cancer
4.1 Cancer Diagnostic Tests
4.1.1 Use of Genomics to Understand Cancer
4.1.2 Molecular Diagnostic Tools Solutions
4.1.3 Technology of Gene Expression Analysis
4.1.3.1 Amplify and Detect Diminished Amounts of RNA Consistently
4.1.3.2 Analyze Hundreds of Genes
4.1.3.3 Employ Advanced Information Technology
4.2 Breast Cancer
4.2.1 Cancer Prognostic Assays
4.2.1.1 Myriad Genetics (BRCA1 and BRCA2)
4.2.1.2 Genomic Health (Oncotype DX)
4.2.1.2.1 Single Gene Reporting (ER, PR, HER2)
4.2.1.2.2 Node Positive
4.2.1.2.3 Aromatase Inhibitors
4.2.1.2.4 Product Development
4.2.1.2.5 Product Development Opportunities in Breast Cancer
4.2.1.3 LabCorp (HER-2)
4.2.1.4 Clarient Diagnostic Services (GE Healthcare)
4.2.1.5 BioTheranostics (AviaraDx)
4.2.1.6 Agendia B.V. (MammaPrint)
4.2.1.7 Genetic Technologies Ltd.
4.2.1.8 Ventana Medical Systems (Roche)
4.2.1.9 Ambry Genetics
4.2.1.10 Counsyl
4.2.1.11 Quest Diagnostics
4.2.1.12 Invitae
4.2.1.13 Gene By Gene
4.2.1.14 Bioreference Laboratories
4.2.1.15 Sophia Genetics
4.2.2 Competition and Comparison of Methods
4.2.2.1 Breast Cancer Molecular Diagnostic Testing Market Size
4.2.2.1.1 Global Market
4.2.2.1.2 U.S. Market
4.2.2.1.3 European Market
4.2.2.2 Market Forecasts
4.2.2.2.1 Revenue Forecasts
4.2.2.3 Market Drivers and Restraints
4.2.2.3.1 Market Drivers
4.2.2.3.2 Market Restraints
4.2.2.4 Breast Cancer Molecular Diagnostic Testing Assay Market and Technology Trends
4.2.2.4.1 Breast Cancer Molecular Diagnostic Testing Assay Market Trends
4.2.2.4.2 Breast Cancer Molecular Diagnostic Testing Assay Technology Trends
4.2.2.4.3 Breast Cancer Testing Assay Strategic Recommendations
4.3 Colorectal Cancer Molecular Diagnostics Market
4.3.1 Colon Cancer Testing Platforms
4.3.1.1 Genomic Testing
4.3.1.1.1 IVD Multiplex Index Analysis
4.3.1.1.2 The BRAF Test
4.3.1.1.3 KRAS
4.3.1.1.3.1 Background on KRAS Mutation
4.3.1.1.4 mSEPT9
4.3.1.2 Screening Test
4.3.2 Players in the Colorectal Cancer Space
4.3.2.1 Agenda
4.3.2.2 BioTheranostics
4.3.2.3 Clarient
4.3.2.4 Genomic Health
4.3.2.5 Epigenomics
4.3.2.6 Exact Sciences
4.3.2.7 Qiagen
4.3.2.8 Arctic Dx
4.3.2.9 Myriad Genetics
4.5.2.7.3 Ovarian Cancer Molecular Diagnostic Testing Assay Strategic Recommendations
4.5.3 Lung Cancer
4.5.4 Melanoma
4.6 Molecular Diagnostic Screening Test for Cancer
4.6.1 Extreme Drug Resistance Assay (Oncotech EDR Assay)
4.6.2 Multidrug Resistance Protein
4.7 Companion Diagnostic Tests for Cancer Therapeutics

5. Business
5.1 Technology and Market Trends
5.1.1 Technology Trends
5.1.2 Market Trends
5.2 M&A Activity
5.3 Partnerships
5.4 Competitive Analysis
5.4.1 Primary Competitors
5.4.1.1 Summary of Market Strengths, Weaknesses, Opportunities and Threats
5.4.2 Industry Challenges and Strategic Recommendations
5.4.3 Commercialization of Molecular Diagnostic Products
5.5 SWOT Comparison of Business Models for Cancer Diagnostic Testing
5.6 Intellectual Property Rights
5.6.1 BRCA1 and BRCA2 Gene Patents
5.6.2 Current Patent Disputes

6. Reimbursement and Billing
6.1 Overview
6.2 Trends in Reimbursement Practice
6.2.1 Medicare Reimbursement
6.2.2 Analysis of ROI for MDx Tests for Cancer Using Medicare Reimbursement Rules
6.2.3 Reimbursement for Oncotype Dx, MammaPrint
6.3 Breast Cancer Tests
6.4 Colon Cancer Tests
6.5 Trends in Patient Care and Reimbursement
6.6 Revenue Threats
6.6.1 Medicare Exceptions
6.6.2 Three Areas for Denial of Claims by Biomarkers
6.7 Billing
6.7.1 Medicare Billing Procedures
6.7.2 Medicare CPT Coding Rules for Cancer Biomarkers

7. Government Regulation
7.1 U.S. Food and Drug Administration
7.2 CLIA Regulations
7.3 Clinical Laboratory Improvement Act
7.4 State Licensing for Service Laboratories
7.5 FDA Treatment of Multivariate Index Assays
7.6 510(k) Clearance
7.7 Pre-Market Approval
7.8 ASRs
7.9 What Regulatory Guidance is Needed for Companion Biomarkers?
7.10 U.S. Patent and Trademark Office
7.11 IRB Approval in Clinical Trials
7.12 Oncology Biomarkers Qualification Initiative Project
7.13 FDA Clearance Picture for Insight Dx, MammaPrint and Oncotype DX
7.14 Microarray Quality Control
7.15 ER and PR Proficiency Testing

8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development
8.1 What are the Key Opportunities for Development of Cancer Tests Based Upon Molecular Diagnostics Technologies?
8.2 What are the Current Obstacles for Implementation of Molecular Diagnostics for Cancer?
8.3 How do Business Strategies, such as those Relating to Acquisition, Drive Biomarker Strategies?
8.4 Which Types of Cancer Testing should be Developed by Molecular Diagnostic Companies at Various
Stages in the Development Pipeline?
8.5 How can Regulatory Oversight Drive Approval and Adoption of New Technologies?
8.6 What are the Noteworthy Deals?
8.7 Who are the Acquirers?
8.8 Who are the Target Companies?
8.9 In what Class of Drugs is the Value of Using Genetic Biomarkers in Decision-Making the Highest?
8.10 How Can Regulatory Oversight Drive Approval and Adoption of New Technologies?
8.11 How can Big Pharma Co-Develop Genetic Biomarkers for Regulatory Acceptance?
8.12 How are Genetic Biomarkers Being Used to Reduce the Attrition Rate in Drug Development?
8.13 How is ROI Measured Using Genetic Biomarkers in Drug Development?
8.14 How might Organizational Structures Limit the Use of Genetic Biomarkers in Drug Development and how should R&D Organizations Address this Problem?
8.15 How to Maximize Business Development through Biomarker Strategies?
8.16 What is the Best Type of Business Model for Developing Genetic Biomarkers?
8.17 What are Organizational Impediments in Genetic Biomarkers in Drug Development?
8.18 What are Internal Capabilities for Novel Biomarker Development and Application?
8.19 How can Key Biomarker Technical Expertise be Applied Across a Complex and Highly-Stratified R&D Value Chain?
8.20 At what Stage of Drug Development has Genetic Biomarkers Provided the most Benefit?
8.21 What Companies are the most Innovative in Development of Genetic Cancer Biomarkers?
8.22 Best Values for Genetic Biomarkers in Drug Development and in Diagnostics
8.23 Molecular Diagnostic Tests can Increase Value in an Associated Drug
8.24 Business Developments in Next Generation Sequencing

9. Company Profiles
9.1 Abbott Molecular Diagnostics
9.2 Accugenomics, Inc.
9.3 Agenda
9.4 Ambry Genetics
9.5 Biodesix
9.6 bioMérieux
9.7 bioTheranostics (AviaraDx)
9.8 Cancer Genetics, Inc.
9.9 Clariant, Inc. (GE Healthcare)
9.10 Counsyl
9.11 Flatiron Health
9.12 Epigenomics
9.13 Exact Sciences Corporation
9.14 Exiqon
9.15 Genomic Health, Inc.
9.16 Genoptix, Inc. (Novartis)
9.17 Genmark Diagnostics
9.18 Genomictree
9.19 HTG Molecular Diagnostics
9.20 Invitae
9.21 LabCorp
9.22 Myriad Genetics, Inc.
9.23 Nanostring
9.24 Neogenomics
9.25 NSTG
9.26 Nuvera Biosciences
9.27 Orion Genomics
9.28 Pathway Genomics
9.29 Personal Genome Diagnostics
9.30 Quest Diagnostics
9.31 Rosetta Genomics Ltd.
9.32 Signal Genetics
9.33 Source MDx
9.34 Wiley, Inc.

Appendix 1: Definition of Terms for Molecular Diagnostics
Appendix 2: Standard Cancer Therapeutic Panels
Table 4.12: Comparison of Agendia vs. Genomic Health Breast Cancer Tests
Table 4.13: Overview of HER2/neu and Herceptin
Table 4.14: MammaPrint: Key Features
Table 4.15: Major Laboratory Testing Companies Marketing Breast Cancer Molecular Diagnostic Tests, 2014
Table 4.16: Global Market for Breast Cancer Molecular Diagnostic Testing, 2005-2014
Table 4.17: U.S. Market for Breast Cancer Molecular Diagnostic Testing, 2005-2014
Table 4.18: Global Market Forecast for Breast Cancer Molecular Diagnostic Testing, 2015-2021
Table 4.19: U.S. Market Forecast for Breast Cancer Molecular Diagnostic Testing, 2015-2021
Table 4.20: Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
Table 4.21: Breast Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact
Table 4.22: Summary of Strengths, Weaknesses, Opportunities and Threats of the Breast Cancer Molecular Diagnostic Market
Table 4.23: Colorectal Cancer Overview
Table 4.24: KRAS Mutation Assay
Table 4.25: KRAS Assays by Analytical Type
Table 4.26: KRAS Mutation Analysis Summary
Table 4.27: DxS KRAS Mutation Test Summary
Table 4.28: KRAS and BRAF in Clinical Use
Table 4.29: Key Players in the Colorectal Cancer Molecular Diagnostic Space
Table 4.30: NexCourse CRC Test Offering and Treatment Direction
Table 4.31: Global Market for Molecular Diagnostic Colon Cancer Testing, 2005-2014
Table 4.32: U.S. Market for Molecular Diagnostic Colon Cancer Testing, 2005-2014
Table 4.33: Global Market Forecast for Colon Cancer Molecular Diagnostic Testing, 2015-2021
Table 4.34: U.S. Market Forecast for Colon Cancer Molecular Diagnostic Testing, 2015-2021
Table 4.35: Colon Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
Table 4.36: Colon Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact
Table 4.37: Summary of Strengths, Weaknesses, Opportunities and Threats of the Colon Cancer Market
Table 4.38: Stages in Prostate Cancer Discovery and Diagnosis
Table 4.39: Corporate Players Entering the Prostate Cancer Molecular Diagnostic Space
Table 4.40: Hologic Genetic Testing Product Line
Table 4.41: Prostate Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact
Table 4.42: Prostate Cancer Molecular Diagnostic Testing Market: Market Restraints Ranked in Order of Impact
Table 4.43: Summary of Strengths, Weaknesses, Opportunities and Threats of the Prostate Cancer Molecular Diagnostic Market
Table 4.44: Players in the Bladder Cancer Molecular Diagnostic Space
Table 4.45: Commercially Available Molecular Diagnostic Products for Ovarian Cancer Assay
Table 4.46: Global Market for Molecular Diagnostic Ovarian Cancer Testing, 2005-2014
Table 4.47: U.S. Market for Molecular Diagnostic Ovarian Cancer Testing, 2005-2014
Table 4.48: Global Market Forecast for Ovarian Cancer Molecular Diagnostic Testing, 2015-2021
Table 4.49: U.S. Market Forecast for Ovarian Cancer Molecular Diagnostic Testing, 2015-2021
Table 4.50: Ovarian Cancer Molecular Diagnostic Testing Market: Market Drivers in Order of Impact
Table 4.51: Ovarian Cancer Molecular Diagnostic Testing Market: Market Restraints in Order of Impact
Table 4.52: Summary of Strengths, Weaknesses, Opportunities and Threats of the Ovarian Cancer Market
Table 4.53: Lung Cancer Survival Rates
Table 4.54: Lung Cancer Facts
Table 4.55: Pharmacogenetic Markers for Select Cancer Drugs
Table 4.56: Potential of Cancer Biomarkers in Drug Delivery and Development
Table 4.57: Barriers to Adoption of Biomarkers in Clinical Use
Table 5.1: Technology Trends in Cancer Testing
Table 5.2: Trends in Theranostics
Table 5.3: Market Trends in Cancer Testing
Table 5.4: Molecular Diagnostics Cancer Market: Market Drivers Ranked in Order of Impact
Table 5.5: Molecular Diagnostics Cancer Market: Market Restraints Ranked in Order of Impact
Table 5.6: Companies that Offer Products to Profile Gene Expression in Breast Cancer
Table 5.7: Principal Competitive Factors in the Cancer Screening Market
Table 5.8: Summary of Strengths, Weaknesses, Opportunities and Threats of the Glucose Point of Care Market
Table 5.9: Molecular Diagnostics Cancer Market: Strategic Recommendations on Molecular Diagnostic Sector Business Functions
Table 5.10: Total U.S. Molecular Diagnostics Cancer Market: Impact of Top Industry Challenges
Table 5.11: Utility of Biomarkers as Companion Diagnostics to Drug Development
Table 6.1: CPT Codes for Tumor Markers
Table 6.2: Genomic Health Oncotype DX Sales, 2006-2014
Table 6.3: Factors Determining Third-Party Payment for Advanced Cancer Tests
Table 7.1: Rules that Affect the Ability of a Cancer Diagnostic Service Lab to Conduct Business
Table 7.2: Focus Areas for the FDA Critical Path Initiative
Table 8.1: Effect of Regulation on MDx Cancer Market Technology Platforms, 2007 and 2015
Table 8.2: Partnerships Between Pharmaceutical and Diagnostic Companies, 2009-Present
Table 9.1: Clarient Molecular/PCR Tests

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1195430/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Molecular Diagnostics in Cancer Testing
Web Address: http://www.researchandmarkets.com/reports/1195430/
Office Code: SCPLHPFT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 8000</td>
</tr>
<tr>
<td>1 - 10 Users:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 12000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr  [ ]  Mrs  [ ]  Dr  [ ]  Miss  [ ]  Ms  [ ]  Prof  [ ]

First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World